Monitoring strategies in adults eligible for pharmacological lipid-lowering therapy.

Cochrane Database Syst RevSep 18, 2026 (epub)
Clinical ResearchCardiologyInternal Medicine (General)

Kamyar Shokraee, Brenda Bongaerts, Petek Eylul Taneri et al.

✦ AI-curated · Sources linked

In 30 seconds

This Cochrane systematic review protocol aims to evaluate the effects of various laboratory monitoring strategies on treatment efficacy and safety in adults eligible for pharmacological lipid-lowering therapy. The review will focus on lipid levels and safety parameters, including hepatic, muscular, and renal functions, in the context of cardiovascular disease prevention.

Key findings

  • The review will assess the impact of monitoring strategies on lipid levels and safety parameters.
  • It will evaluate the frequency and timing of monitoring in adults receiving lipid-lowering therapy.
  • The study includes both primary and secondary prevention of cardiovascular disease.

Why it matters

Understanding the optimal monitoring strategies for lipid-lowering therapy is crucial for ensuring treatment efficacy and minimizing adverse effects, which can enhance patient outcomes in cardiovascular disease prevention.

Source

PubMed · PMID 42757711

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.